Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MLTX

MoonLake Immunotherapeut... (MLTX)

MoonLake Immunotherapeutics
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MLTX
DateTimeSourceHeadlineSymbolCompany
08/01/202523:00GlobeNewswire Inc.MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimabNASDAQ:MLTXMoonLake Immunotherapeutics
19/12/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
14/11/202400:00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisNASDAQ:MLTXMoonLake Immunotherapeutics
07/11/202423:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
07/11/202423:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
07/11/202423:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
09/10/202407:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
11/09/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
09/09/202421:00GlobeNewswire Inc.MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11NASDAQ:MLTXMoonLake Immunotherapeutics
07/08/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
07/08/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
07/08/202422:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11NASDAQ:MLTXMoonLake Immunotherapeutics
11/06/202406:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
10/06/202422:00GlobeNewswire Inc.MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisNASDAQ:MLTXMoonLake Immunotherapeutics
08/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
08/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
08/06/202406:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
08/06/202406:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
06/06/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
16/05/202422:00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaNASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202422:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202422:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202421:57Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MLTXMoonLake Immunotherapeutics
10/04/202421:00GlobeNewswire Inc.MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions NASDAQ:MLTXMoonLake Immunotherapeutics
10/04/202421:00Business WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsNASDAQ:MLTXMoonLake Immunotherapeutics
11/03/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
11/03/202403:00GlobeNewswire Inc.MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayNASDAQ:MLTXMoonLake Immunotherapeutics
05/03/202400:00GlobeNewswire Inc.MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024NASDAQ:MLTXMoonLake Immunotherapeutics
01/03/202411:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
 Showing the most relevant articles for your search:NASDAQ:MLTX

Your Recent History

Delayed Upgrade Clock